Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 6 December 2013 a two-year-old boy called Emile Ouamouno died of a serious illness in a small village in Guinea. A month later Emile’s three-year-old sister, his mother and grandmother were all dead.

This was the start of an Ebola epidemic that swept through West Africa in 2014, killing over 11,000 people and infecting nearly 30,000. The World Health Organization (WHO) called it ‘the largest and the most complex Ebola outbreak since the Ebola virus was first discovered in 1976’. An Ebola infection results in high fever, diarrhoea, vomiting, impaired kidney and liver function and, in some cases, internal and external bleeding; fatality rates can be as high as 90%. There are no licensed treatments or vaccines for the disease, and in August 2014 the WHO declared the West African Ebola outbreak ‘a Public Health Emergency of International Concern’.

Read more (pdf)  

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.